XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTIn April 2022, a company in our Life Sciences Portfolio received a certain drug approval from the United States Food and Drug Administration. In connection with the approval, Acacia is due a milestone payment in the approximate amount of $25.6 million to be received in the form of a deferred payment, due and payable in October 2022, with interest accrued at 8.5% per year. Refer to Note 3 for additional information.